362 related articles for article (PubMed ID: 26589238)
61. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
62. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
63. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
[TBL] [Abstract][Full Text] [Related]
64. Preconception SGLT2 or DPP4 inhibitor use and adverse pregnancy outcomes.
Ray JG; Harel Z; Gilbert RE; Wald R; Berger H; Park AL
Diabetes Res Clin Pract; 2023 Nov; 205():110946. PubMed ID: 37813164
[TBL] [Abstract][Full Text] [Related]
65. [Optimizing basal insulin therapy in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2017 Mar; 72(3):156-161. PubMed ID: 28387494
[TBL] [Abstract][Full Text] [Related]
66. Effect of dual inhibition of DPP4 and SGLT2 on tacrolimus-induced diabetes mellitus and nephrotoxicity in a rat model.
Ko EJ; Shin YJ; Cui S; Lim SW; Chung BH; Yang CW
Am J Transplant; 2022 Jun; 22(6):1537-1549. PubMed ID: 35294797
[TBL] [Abstract][Full Text] [Related]
67. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.
Yin R; Xu Y; Wang X; Yang L; Zhao D
Molecules; 2022 May; 27(10):. PubMed ID: 35630534
[TBL] [Abstract][Full Text] [Related]
68. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.
Sharma MD
Diabetes Obes Metab; 2015 Jul; 17(7):616-21. PubMed ID: 25690671
[TBL] [Abstract][Full Text] [Related]
69. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
70. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
71. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
72. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862004
[TBL] [Abstract][Full Text] [Related]
73. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
74. Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain.
Cuatrecasas G; Goñi-Goicoechea F
Med Clin (Barc); 2016 Nov; 147 Suppl 1():30-34. PubMed ID: 28760223
[TBL] [Abstract][Full Text] [Related]
75. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
76. Sitagliptin for Type 2 diabetes: a 2015 update.
Lee M; Rhee MK
Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
[TBL] [Abstract][Full Text] [Related]
77. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
Carramiñana Barrera FC
Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
[TBL] [Abstract][Full Text] [Related]
78. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
79. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
80. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
